Cagri Kiziltunc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cagri Kiziltunc has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Burcin Meryem Atak Tel
Abant Izzet Baysal University Hospital
1 shared publication - Buse Balci
Department of Internal Medicine, Abant Izzet Baysal University Hospital, 14200 Bolu, Turkey
1 shared publication - Eray Erge
Department of Internal Medicine Abant Izzet Baysal University Hospital Bolu Turkey
1 shared publication - Gulali Aktas
Bolu Abant İzzet Baysal University
1 shared publication - Gülden Sincan
Department of Hematology, Medical School, Ataturk University, Erzurum, Turkey
1 shared publication İsTemi Serin
Department of Hematology, Başakşehir Çam and Sakura City Hospital, Erzurum, Turkey
1 shared publication
Latest Publications
- Open Access
- 3 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (40) , e44378
The clinical significance of p53 and vascular endothelial growth factor in COVID-19 cases
Vascular endothelial growth factor (VEGF) plays a critical role in increasing the release of pro-inflammatory cytokines, endothelial cell proliferation, and regulating vascular permeability in COVID-19 cases. p53 regulates cellular stress responses. However, the precise interplay and prognostic significance of p53 and vascular endothelial growth factor in the context of COVID-19 pathogenesis and disease progression, particularly concerning mortality outcomes, remain to be fully elucidated. We investigated vascular endothelial growth factor and p53 levels in COVID-19 patients and examined the relationship of these markers with the clinical course and prognosis of the disease. A total of 30 patients with COVID-19 and 30 individuals in the control group were examined. The clinical symptoms, laboratory parameters, and survival status of COVID-19 patients participating in the study were recorded. Vascular endothelial growth factor and p53 levels were analyzed using the ELISA method. A P -value of < 0.05 was considered statistically significant in statistical analyses. p53 levels were significantly higher in COVID-19 patients (859.19 ± 385.43 ng/L) compared to the control group (727.29 ± 440.49 ng/L) ( P = .04). There was no significant difference in vascular endothelial growth factor levels between the patient (126.52 ± 75.7 ng/L) and control groups (169.2 ± 112.3 ng/L) ( P = .22). In deceased patients, both p53 and vascular endothelial growth factor levels were significantly higher than in the control group ( P < .001, P = .03, respectively). This study supports the prognostic roles of p53 and vascular endothelial growth factor levels in COVID-19 disease.
- 3 October 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (40) , e44378
Open AccessThe clinical significance of p53 and vascular endothelial growth factor in COVID-19 cases
Vascular endothelial growth factor (VEGF) plays a critical role in increasing the release of pro-inflammatory cytokines, endothelial cell proliferation, and regulating vascular permeability in COVID-19 cases. p53 regulates cellular stress responses. However, the precise interplay and prognostic significance of p53 and vascular endothelial growth factor in the context of COVID-19 pathogenesis and disease progression, particularly concerning mortality outcomes, remain to be fully elucidated. We investigated vascular endothelial growth factor and p53 levels in COVID-19 patients and examined the relationship of these markers with the clinical course and prognosis of the disease. A total of 30 patients with COVID-19 and 30 individuals in the control group were examined. The clinical symptoms, laboratory parameters, and survival status of COVID-19 patients participating in the study were recorded. Vascular endothelial growth factor and p53 levels were analyzed using the ELISA method. A P -value of < 0.05 was considered statistically significant in statistical analyses. p53 levels were significantly higher in COVID-19 patients (859.19 ± 385.43 ng/L) compared to the control group (727.29 ± 440.49 ng/L) ( P = .04). There was no significant difference in vascular endothelial growth factor levels between the patient (126.52 ± 75.7 ng/L) and control groups (169.2 ± 112.3 ng/L) ( P = .22). In deceased patients, both p53 and vascular endothelial growth factor levels were significantly higher than in the control group ( P < .001, P = .03, respectively). This study supports the prognostic roles of p53 and vascular endothelial growth factor levels in COVID-19 disease.
- Open Access
A Novel Inflammatory Marker for the Diagnosis of Hashimoto’s Thyroiditis: Platelet-Count-to-Lymphocyte-Count Ratio
Background: Hashimoto’s thyroiditis (HT) is a chronic autoimmune thyroiditis that causes systemic inflammation in the body, leading to hypothyroidism and an enlargement of the thyroid gland. Objectives: This study aims to reveal whether there is a relationship between Hashimoto’s thyroiditis and the platelet-count-to-lymphocyte-count ratio (PLR), which is used as a new inflammatory marker. Methods: In this retrospective study, we compared the PLR of the euthyroid HT group and the hypothyroid-thyrotoxic HT group to the controls. We also evaluated the values of thyroid-stimulating hormone (TSH), free T4 (fT4), C-reactive protein (CRP), aspartate transaminase (AST), alanine transaminase (ALT), white blood cell count, lymphocyte count, hemoglobin, hematocrit, and platelet count in each group. Results: The PLR of the subjects with Hashimoto’s thyroiditis was found to be significantly different from the control group (p < 0.001), with the rankings as follows: hypothyroid-thyrotoxic HT 177% (72–417) > euthyroid HT 137% (69–272) > control group 103% (44–243). In addition to the increased PLR values, an increase in CRP values was also observed, revealing a strong positive correlation between the PLR and CRP in the HT patients. Conclusion: In this study, we found out that the PLR was higher in the hypothyroid-thyrotoxic HT and euthyroid HT patients than in a healthy control group.
Open AccessA Novel Inflammatory Marker for the Diagnosis of Hashimoto’s Thyroiditis: Platelet-Count-to-Lymphocyte-Count Ratio
Background: Hashimoto’s thyroiditis (HT) is a chronic autoimmune thyroiditis that causes systemic inflammation in the body, leading to hypothyroidism and an enlargement of the thyroid gland. Objectives: This study aims to reveal whether there is a relationship between Hashimoto’s thyroiditis and the platelet-count-to-lymphocyte-count ratio (PLR), which is used as a new inflammatory marker. Methods: In this retrospective study, we compared the PLR of the euthyroid HT group and the hypothyroid-thyrotoxic HT group to the controls. We also evaluated the values of thyroid-stimulating hormone (TSH), free T4 (fT4), C-reactive protein (CRP), aspartate transaminase (AST), alanine transaminase (ALT), white blood cell count, lymphocyte count, hemoglobin, hematocrit, and platelet count in each group. Results: The PLR of the subjects with Hashimoto’s thyroiditis was found to be significantly different from the control group (p < 0.001), with the rankings as follows: hypothyroid-thyrotoxic HT 177% (72–417) > euthyroid HT 137% (69–272) > control group 103% (44–243). In addition to the increased PLR values, an increase in CRP values was also observed, revealing a strong positive correlation between the PLR and CRP in the HT patients. Conclusion: In this study, we found out that the PLR was higher in the hypothyroid-thyrotoxic HT and euthyroid HT patients than in a healthy control group.